Table 4.

Results of network meta-analyses for adverse event rate.

OR (95% CI)
Ome
0.97 (0.78, 1.21)	Lan
0.93 (0.68, 1.28)	0.96 (0.69, 1.34)	Pan
0.97 (0.61, 1.52)	0.99 (0.60, 1.64)	1.04 (0.60, 1.80)	Rab
0.97 (0.83, 1.14)	1.00 (0.87, 1.16)	1.05 (0.77, 1.41)	1.01 (0.62, 1.63)	Eso
0.90 (0.46, 1.76)	0.93 (0.48, 1.80)	0.97 (0.47, 1.98)	0.93 (0.41, 2.09)	0.92 (0.48, 1.77)	Ila
0.91 (0.65, 1.27)	0.93 (0.72, 1.21)	0.98 (0.64, 1.49)	0.94 (0.53, 1.66)	0.93 (0.69, 1.26)	1.01 (0.49, 2.06)	Von
0.82 (0.51, 1.32)	0.84 (0.51, 1.40)	0.88 (0.56, 1.38)	0.85 (0.44, 1.64)	0.84 (0.52, 1.36)	0.91 (0.41, 2.05)	0.90 (0.51, 1.59)	Pla

CI = confidence interval; Eso = esomeprazole, 40 mg/d; Ila = ilaprazole, 10 mg/d; Lan = lansoprazole, 30 mg/d; Ome = omeprazole, 20 mg/d; OR = odds ratio; Pan = pantoprazole, 40 mg/d; PLA = placebo; Rab = rabeprazole, 20 mg/d; Von = vonoprazan 20 mg/d.